Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
281 hedge funds and large institutions have $7.28B invested in Apellis Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 106 increasing their positions, 78 reducing their positions, and 28 closing their positions.
143% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 28
71% more call options, than puts
Call options by funds: $182M | Put options by funds: $106M
40% more capital invested
Capital invested by funds: $5.2B → $7.28B (+$2.08B)
36% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 78
15% more funds holding
Funds holding: 244 → 281 (+37)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
5.53% more ownership
Funds ownership: 90.89% → 96.42% (+5.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$108M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$106M |
| 3 |
O
OrbiMed
New York
|
+$52.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$40M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$31.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$28.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$27.7M |
| 4 |
Goldman Sachs
New York
|
-$23M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$20.1M |
APLS Hedge Fund Activity: Q1 2023 in Review
281 of the 6,278 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2023, worth a combined $7.28B — up 40% from $5.2B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new APLS positions and 28 closed out — a net gain of 40 holders — while 106 added to existing stakes and 78 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $108M. The largest seller was Logos Global Management, cutting an estimated $31.7M.
- 281 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2023, up from 244 in Q4 2022.
- Funds reported $7.28B of Apellis Pharmaceuticals stock for Q1 2023, up 40% quarter-over-quarter.
- 68 funds opened new Apellis Pharmaceuticals positions in Q1 2023 and 28 closed out, a net change of +40 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2023 was Point72 Asset Management, an estimated $108M added.
- The largest Apellis Pharmaceuticals seller in Q1 2023 was Logos Global Management, an estimated $31.7M sold.
Based on aggregated 13F filings for Q1 2023.